On ECHEMI
Home > Drugs > Jinyao Darrentang Group Co., Ltd. Xinxin Pharmaceutical Factory
Jinyao Darrentang Group Co., Ltd. Xinxin Pharmaceutical Factory
  • Founded in:

    2000-10-20
  • Country:

    China China
  • Address:

    Chenglinzhuang Industrial Zone, Tianjin
  • Tax NO.:

    91120110103738323L
  • Registered Funds:

    -
  • Email:

Related Drugs
Ticlopidine Hydrochloride Tablets
The main ingredient of this product is: Ticlopidine hydrochloride.
Name Description Content CAS NO. Registered Holders
Ticlopidine hydrochloride

Antiplatelet aggregation drugs can inhibit platelet aggregation caused by various inducers such as ADP, collagen, thrombin, arachidonic acid and prostaglandin endoperoxides, and can inhibit platelet aggregation reactions induced by exogenous and endogenous ADP.

More

Antiplatelet aggregation drugs can inhibit platelet aggregation caused by various inducers such as ADP, collagen, thrombin, arachidonic acid and prostaglandin endoperoxides, and can inhibit platelet aggregation reactions induced by exogenous and endogenous ADP.

53885-35-1 22
Tiapride Hydrochloride
Name Description Content CAS NO. Registered Holders
Tiapride hydrochloride

Extract from the above information

More

Extract from the above information

51012-33-0 11
Metformin Hydrochloride
Metformin Hydrochloride
Name Description Content CAS NO. Registered Holders
1,1-DIMETHYLBIGUANIDE HYDROCHLORIDE

This product is a hypoglycemic drug. Its pharmacological effects include: 1. Increase the sensitivity of peripheral tissues to insulin and increase insulin-mediated glucose utilization; 2. Increase the utilization of glucose by non-insulin-dependent tissues; 3. Inhibit hepatic gluconeogenesis and reduce hepatic glucose output; 4. Inhibit intestinal wall cells from taking up glucose; 5. Inhibit the biosynthesis and storage of cholesterol and reduce blood triglyceride and total cholesterol levels. Unlike insulin, this product does not promote fat synthesis and has no obvious hypoglycemic effect on normal people. It generally does not cause hypoglycemia when used alone for type 2 diabetes.

More

This product is a hypoglycemic drug. Its pharmacological effects include: 1. Increase the sensitivity of peripheral tissues to insulin and increase insulin-mediated glucose utilization; 2. Increase the utilization of glucose by non-insulin-dependent tissues; 3. Inhibit hepatic gluconeogenesis and reduce hepatic glucose output; 4. Inhibit intestinal wall cells from taking up glucose; 5. Inhibit the biosynthesis and storage of cholesterol and reduce blood triglyceride and total cholesterol levels. Unlike insulin, this product does not promote fat synthesis and has no obvious hypoglycemic effect on normal people. It generally does not cause hypoglycemia when used alone for type 2 diabetes.

15537-72-1 55
Metformin Hydrochloride Tablets
The main ingredient of this product is metformin hydrochloride, and its chemical name is 1,1-dimethylbiguanide hydrochloride.
Name Description Content CAS NO. Registered Holders
1,1-DIMETHYLBIGUANIDE HYDROCHLORIDE

This product is a hypoglycemic drug. It can reduce fasting and postprandial hyperglycemia in patients with type 2 diabetes, and HbAlc can be reduced by 1% to 2%. Its hypoglycemic mechanism may be: 1. Increase the sensitivity of peripheral tissues to insulin and increase insulin-mediated glucose utilization; 2. Increase the utilization of glucose by non-insulin-dependent tissues, such as the brain, blood cells, renal medulla, intestines, skin, etc.; 3. Inhibit hepatic gluconeogenesis and reduce hepatic glucose output; 4. Inhibit intestinal wall cells from taking up glucose; 7. Inhibit the biosynthesis and storage of cholesterol and reduce blood triglyceride and total cholesterol levels. Unlike the effect of insulin, this product has no effect on promoting fat synthesis and no obvious hypoglycemic effect on normal people, but has a good therapeutic effect on type 2 diabetes.

More

This product is a hypoglycemic drug. It can reduce fasting and postprandial hyperglycemia in patients with type 2 diabetes, and HbAlc can be reduced by 1% to 2%. Its hypoglycemic mechanism may be: 1. Increase the sensitivity of peripheral tissues to insulin and increase insulin-mediated glucose utilization; 2. Increase the utilization of glucose by non-insulin-dependent tissues, such as the brain, blood cells, renal medulla, intestines, skin, etc.; 3. Inhibit hepatic gluconeogenesis and reduce hepatic glucose output; 4. Inhibit intestinal wall cells from taking up glucose; 7. Inhibit the biosynthesis and storage of cholesterol and reduce blood triglyceride and total cholesterol levels. Unlike the effect of insulin, this product has no effect on promoting fat synthesis and no obvious hypoglycemic effect on normal people, but has a good therapeutic effect on type 2 diabetes.

15537-72-1 55
Sodium Alginate Diester Tablets
The main ingredients of this product are: sodium alginate diester.
Name Description Content CAS NO. Registered Holders
Alginic Sodium Diester

It has many functions, such as improving the viscoelasticity of blood rheology, anti-coagulation, anti-thrombosis, lowering blood viscosity, relieving spasm of micro-arteries and veins, disaggregation of red blood cells and platelets, lowering blood lipids, inhibiting atherosclerosis, dilating peripheral blood vessels, improving microcirculation, inhibiting arteriovenous thrombosis, lowering blood sugar and blood pressure.

More

It has many functions, such as improving the viscoelasticity of blood rheology, anti-coagulation, anti-thrombosis, lowering blood viscosity, relieving spasm of micro-arteries and veins, disaggregation of red blood cells and platelets, lowering blood lipids, inhibiting atherosclerosis, dilating peripheral blood vessels, improving microcirculation, inhibiting arteriovenous thrombosis, lowering blood sugar and blood pressure.

9005-40-7 11
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.